Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - Should You Sell?

Key Points

• Ascentage Pharma Group International shares gapped down from a previous close of $40.46 to open at $38.63, reflecting a 4.5% decline.
• Institutional investors have shown interest with multiple firms, including Monashee Investment Management, acquiring significant new stakes in the company during recent quarters.
• The company focuses on developing novel therapies for cancers, hepatitis B, and age-related diseases, and is classified as a clinical-stage biotechnology firm based in Suzhou, China.

Shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - ) gapped down prior to trading on Tuesday . The stock had previously closed at $40.46, but opened at $38.63. Ascentage Pharma Group International shares last traded at $38.63, with a volume of 298 shares traded.

Ascentage Pharma Group International Stock Down 4.5%

The business's 50 day moving average is $40.95 and its 200 day moving average is $30.87. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Chevy Chase Trust Holdings LLC purchased a new stake in Ascentage Pharma Group International in the 2nd quarter worth $227,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International in the 2nd quarter worth $391,000. Tema Etfs LLC purchased a new stake in Ascentage Pharma Group International in the 2nd quarter worth $610,000. Finally, Monashee Investment Management LLC acquired a new stake in Ascentage Pharma Group International during the 1st quarter worth $3,511,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.